...
首页> 外文期刊>Journal of Molecular and Cellular Cardiology >Cardiac myosin-binding protein C in hypertrophic cardiomyopathy: mechanisms and therapeutic opportunities.
【24h】

Cardiac myosin-binding protein C in hypertrophic cardiomyopathy: mechanisms and therapeutic opportunities.

机译:肥厚型心肌病中心肌肌球蛋白结合蛋白C的作用机理和治疗机会。

获取原文
获取原文并翻译 | 示例
           

摘要

Cardiac myosin-binding protein C (cMyBP-C) is a component of the thick filaments of the sarcomere. Understanding the structural and functional role of cMyBP-C in the heart is clinically relevant since cMyBP-C gene mutations are a widely recognized cause of hypertrophic cardiomyopathy (HCM), which affects 0.2% of the general population. Nonsense and frameshift mutations are common in cMyBP-C and their expressions are regulated by three quality control systems, the nonsense-mediated mRNA decay, ubiquitin-proteasome system, and autophagy, which contribute to minimize the production of potential poison mutant proteins. This review discusses the structural and regulatory functions of cMyBP-C, the molecular mechanisms involved in cMyBP-C-related HCM, as well as potential causative therapies for HCM.
机译:心肌肌球蛋白结合蛋白C(cMyBP-C)是肌节粗丝的组成部分。了解cMyBP-C在心脏中的结构和功能作用与临床相关,因为cMyBP-C基因突变是肥厚型心肌病(HCM)的广为公认的病因,影响了总人口的0.2%。无意义和移码突变在cMyBP-C中很常见,其表达受三种质量控制系统调节,即无意义介导的mRNA衰变,泛素-蛋白酶体系统和自噬,这有助于最大程度地减少潜在的毒性突变蛋白的产生。这篇综述讨论了cMyBP-C的结构和调节功能,与cMyBP-C相关的HCM涉及的分子机制以及HCM的潜在致病性疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号